Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.
Harshavardhan Sai Sadineni and Srived Meda of Kasturba Medical College, Manipal, India, won the XVIII Fujio Cup Quiz (FCQ) on Stem cells and Regenerative medicine (RM) in the NCRM NICHE 2023; Sri Ramachandra Institute for Higher Education and Research, India and Institut Teknologi Bandung, Indonesia emerged as runners and joined the team of FCQ elites, a privilege bestowed on those who reach the final stage of the multi-level international contest including a quiz in RM, thereby qualifying to nominate the candidate(s) to Edogawa NICHE Prize, instituted in 2018. The Edogawa NICHE Prize awardee of 2020, Dr John Craig Venter will deliver his lecture at the UHN Ajmera Transplant Center, on the 25th October 2023, in conjunction with the Training Program in Regenerative Medicine (TPRM) at the University of Toronto, co-hosted by German Society for Stem Cell Research (GSZ).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017068457/en/
Bringing together, all stakeholders involved in research on physical, chemical, and biological realms, biomaterials, and tissue engineering systems to develop novel solutions in regenerative medicine has been the major goal and accomplishment of NCRM NICHE, in the past 18 years. Winners and finalists of Fujio Cup Quiz (FCQ), the “FCQ Elites” are qualified to nominate the candidates for the Edogawa NICHE Prize. The inaugural prize in 2018 was awarded to Prof. James E. Till for discovery of stem cells, jointly with Prof. Ernest McCulloch. 2019 prize was awarded to Dr. Steven A. Rosenberg, for his pioneering work in adoptive immunotherapies and in 2020 to Dr. John Craig Venter for his research in synthetic biology and the human genome. NCRM NICHE team is progressing in research on implications of microgravity, synthetic chemical concoctions, and biological response modifiers, on cellular senescence and immune modulation to develop solutions, especially for rare diseases and unmet needs. (Graphic: Business Wire)
FCQ is an active knowledge gaining event in RM started in 2006 in India, as a part of NCRM NICHE, the inaugural anniversary commemorative event of Nichi-in Centre for Regenerative medicine (NCRM), held every October, conducted in Tokyo 2017~2019, and now virtually. NCRM NICHE has triggered novel ideas and collaborations yielding cutting edge solutions in cell therapies such as the Buccal epithelium Expanded and Encapsulated in Scaffold-Hybrid Approach to Urethral Stricture (BEES HAUS) with clinical studies of safety & efficacy and preclinical evidence, tissue engineering technologies for transplant suitable human chondrocytes for cartilage repair with age reversal in vitro, optimized solutions for transport of cells and tissues for processing between hospitals and cell processing facilities. Through a global inter-disciplinary networking, disease modifying adjunct solutions developed for unmet needs viz., Duchenne muscular dystrophy (DMD), multiple sclerosis (MS), Autism spectrum disorders (ASD), and Parkinson’s disease (PD), were presented in the Inter-disciplinary Conclave (IDC).
Prof. Dr. Mihai G. Netea, Radboud University Medical Center, Netherlands, talked on Trained immunity and innate host defense, Dr Shojiro Katoh, President, Edogawa Hospital, on Novel tissue engineering technology enhancing cell therapies for cartilage repair, Mr. Yasutoshi Nishikawa, on Biomaterials for bone reconstruction and Dr Dedeepiya Devaprasad, on Gut microbiome, Gut-brain-axis & Brain health, moderated by Prof. Dr. Jurgen Hescheler, University of Cologne, Germany.
NCRM with cell biology and biomaterial laboratories, in collaboration with academic and industry partners in Japan are researching on the basic origin of diseases at cellular level taking cues from immune system evolution across phylogeny, in vitro culture systems and in vivo biological responders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231017068457/en/
Contact information
Samuel JK Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 14:00:00 EEST | Press release
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades. The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefi
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 14:00:00 EEST | Press release
As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s coming next,” said Andrew Busch, economic futurist and economist at AndrewBusch.com. “Tariffs are no longer just a policy lever; they’re a strategic force reshaping the g
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 13:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce the company’s strategic vision to redefine the standard of care for B-cell malignancies. “The data presented at EHA 2025 underscore the strength of BeOne’s comprehensive hematology pipeline, built on the success of BRUKINSA, the only BTK inhibitor to demonstrate superior progression-free survival over ibrutinib in a Phase 3 trial,1” said Lai Wang, Ph.D. Global Head of R&D at BeOne. “With our potentially best-in-class BCL2 inhibitor, sonrotoclax, and fi
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 11:17:00 EEST | Press release
Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involvement in the IPCEI-CIS project, along with partnerships with Deutsche Telekom AG, NVIDIA, Telefónica, a
SmartStream Brings AI-Powered Data Management to the Insurance Sector12.6.2025 10:00:00 EEST | Press release
SmartStream, the financial Transaction Lifecycle Management (TLM®) and solutions provider, has announced the expansion of its AI-driven reconciliation and data management platform, SmartStream Air, into the insurance sector. This move aims to help insurers tackle fragmented data challenges, reduce operational costs, and strengthen compliance through robust audit trails. As the insurance industry struggles with limited digital maturity, it faces mounting pressure from increasing transaction volumes, persistent data quality issues, and the complex demands of evolving regulations such as IFRS 17 and DORA. In this environment, the need for advanced, rapidly deployable SaaS data management solutions has never been more urgent. Addressing these challenges requires a fundamental transformation in how insurers manage systems, streamline operations, and ensure data integrity across the enterprise. SmartStream Air leverages cutting-edge AI to reconcile and manage high volumes of data, for exampl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom